Fieldpoint Private Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Fieldpoint Private Securities’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Sell	16 -40	-71%	-$2.27K	﹤0.01%	1361
2022 Q1	$4K	Sell	56 -88	-61%	-$6.38K	﹤0.01%	1339
2021 Q4	$14K	Sell	144 -8	-5%	-$739	﹤0.01%	984
2021 Q3	$13K	Hold	152	–	–	﹤0.01%	962
2021 Q2	$10K	Hold	152	–	–	﹤0.01%	1019
2021 Q1	$14K	Hold	152	–	–	﹤0.01%	896
2020 Q4	$9K	Buy	+152	New	+$8.67K	﹤0.01%	948

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fieldpoint Private Securities's LGND Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Ligand Pharmaceuticals (LGND) stake by 71% in Q2 2022, selling an estimated $2.27K and leaving 16 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Fieldpoint Private Securities first reported a position in LGND in Q4 2020 and has held it in 7 quarters since. The position peaked at $14K in Q4 2021. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.

Fieldpoint Private Securities held 16 shares of Ligand Pharmaceuticals worth $1K as of Q2 2022.
Fieldpoint Private Securities sold 40 Ligand Pharmaceuticals shares in Q2 2022, an estimated $2.27K.
Ligand Pharmaceuticals made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1361 holding.
Fieldpoint Private Securities first reported a position in Ligand Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Ligand Pharmaceuticals position peaked at $14K in Q4 2021.
197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.